Therapeutic Response

Wild type KRAS and Wild type NRAS status confers therapeutic sensitivity to Cetuximab in combination with Fluorouracil and Irinotecan in patients with Colorectal Adenocarcinoma.

Statements

Source and description

Cetuximab (7 days) and FOLFIRI (14 days) Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (7 days) in combination with FOLFIRI (14 days) for reimbursement as a treatment option for the treatment of adult patients with RAS wild type metastatic colorectal cancer. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.